2,992
回編集
差分
ナビゲーションに移動
検索に移動
→Interactions of MenACWY conjugate vaccines and other vaccines
{|class="wikitable"
|-
! !!Men-ACWY-DT!!Men-ACWYMenACWY-DT|-*conjugated with diphtheria toxoid! !!*メナクトラ Menactra!!MenACWY-TT*conjugated with tetanus toxoid*メンクアッドフィ MenQuadfi
|-
!PCV7
*conjugated with DT
|
*In a clinical trial of Menactra<sup>1)</sup>
*Concomitant administration of Menactra+PCV7 at 12 months of age showed '''unmet non-inferiority criteria of pneumococcal IgG in 3 serotypes''' out of 7 in PCV7
|
|-
!PCV13
*conjugated with DT
|
|
*MenQuadfi+PCV13 can be administered concomitantly<sup>2)</sup>, though SBA of serogroup A was lower of unknown clinical relevance
|-
!Td
|
*In an RCT<sup>1)</sup>
*Serum bactericidal assay (SBA) titers of serogroups C, W and Y in 11-17 years of age were '''higher in concomitant administration of Menactra+Td''' than single Menactra
|
|-
!DTaP
*containing DT & TT
|
*In an RCT<sup>1)</sup>
*SBA titers of all 4 serogroups in 4-6 years of age were '''lower in [DTaP (DAPTACEL) → 30days → Menactra]''' than in [Menactra → 30days → DTaP (DAPTACEL)]
|
|-
!Tdap
*containing DT & TT
|
|
*MenQuadfi+Tdap can be administered concomitantly<sup>2)</sup>, though antibody titer against pertussis antigen PT was non-inferior whereas titers against pertussis FHA, RPN and FIM were lower of unknown clinical relevance
|}
{{quote|content=
*1) [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d8781ff-9366-462c-8161-6e958f44fcb4 14.3 Concomitant Vaccine Administration, Drug LabelInformation, MENACTRA. DailyMed, National Library of Medicine] (last accessed 15th Feb 2023)
*2) [https://www.ema.europa.eu/documents/product-information/menquadfi-epar-product-information_en.pdf 4.5 Interaction with other medicinal products and other forms of interaction, MenQuadfi:EPAR-Product information, European Medicines Agency] (last accessed 15th Feb 2023)
}}
